Back
Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group.
Journal article

Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group.

  • Jeger RV University Hospital Basel, University of Basel, Basel, Switzerland. Electronic address: raban.jeger@usb.ch.
  • Eccleshall S Norfolk and Norwich University Hospital, Norwich, United Kingdom.
  • Wan Ahmad WA University Malaya Medical Centre, Kuala Lumpur, Malaysia.
  • Ge J Zhongshan Hospital, Fudan University, Shanghai, China.
  • Poerner TC Marienhospital, Aachen, Germany.
  • Shin ES Ulsan Medical Center, Ulsan Hospital, Ulsan, South Korea.
  • Alfonso F Hospital Universitario de La Princesa, IIS-IP, CIBER-CV, Madrid, Spain.
  • Latib A Montefiore Medical Center, New York, New York.
  • Ong PJ Tan Tock Seng Hospital, Singapore, Singapore.
  • Rissanen TT Central Hospital of North Karelia, Joensuu, Finland.
  • Saucedo J Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Scheller B University Hospital Saarland, Homburg, Germany.
  • Kleber FX Paul Gerhardt Stift, Wittenberg, Germany.
Show more…
  • 2020-06-01
Published in:
  • JACC. Cardiovascular interventions. - 2020
consensus statement
coronary artery disease
drug-coated balloon
English Although drug-eluting stents are still the default interventional treatment of coronary artery disease, drug-coated balloons (DCBs) represent a novel alternative therapeutic strategy in certain anatomic conditions. The effect of DCBs is based on the fast and homogenous transfer of antiproliferative drugs into the vessel wall during single balloon inflation by means of a lipophilic matrix without the use of permanent implants. Although their use is established for in-stent restenosis of both bare-metal and drug-eluting stents, recent randomized clinical data demonstrate a good efficacy and safety profile in de novo small-vessel disease and high bleeding risk. In addition, there are other emerging indications (e.g., bifurcation lesions, large-vessel disease, diabetes mellitus, acute coronary syndromes). Because the interaction among the different delivery balloon designs, doses, formulations, and release kinetics of the drugs used is important, there seems to be no "class effect" of DCBs. On the basis of the amount of recently published data, the International DCB Consensus Group provides this update of previous recommendations summarizing the historical background, technical considerations such as choice of device and implantation technique, possible indications, and future perspectives.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/250763
Statistics
Document views: 24 File downloads: